通讯作者: 郝小鹰

DOI：10.12201/bmr.202502.00030

Clinical Research Progress of Gastrin in Gastric Precancerous Lesion

• 摘要：胃癌前病变(Gastric Precancerous Lesion,GPL)是胃癌(Gastric cancer,GC)发生发展过程中必经阶段,早期筛查GPL,能够有效降低GC发病率和死亡率。目前,早期筛查GPL可以依靠血清肿瘤标志物,如胃蛋白酶原I/II(PG I/II)、糖类抗原72-4(CA72-4)、糖类抗原19-9(CA19-9)、糖类抗原24-2 (CA24-2)、糖类抗原50(CA50)及胃泌素17(G-17)等,通过检测血清肿瘤标志物的水平,反映胃黏膜病变程度和早期诊治。其中胃泌素17(G-17)在GPL筛查中特异性最高,研究发现,G-17能够反映不同部位的胃黏膜分泌状态、萎缩程度,其血清水平随萎缩程度加重而下降。因此,本文以“Gastrin,Stomach Neoplasms,Precancerous Conditions,Clinical Studies”为英文关键词,以“胃泌素,胃癌,胃癌前病变,临床研究”为中文主题词检索PubMed与中国知网相关文献,检索时间为2019-2024年,纳入近5年相关文献19篇。论述G-17在筛查GPL中的应用的价值,为临床筛查GPL提供更多的参考。

  关键词： 胃泌素; 胃癌前病变; 临床研究; 综述

   

  Abstract: Gastric Precancerous Lesion (GPL) is a necessary stage in the development of gastric cancer (GC), and early screening of GPL can effectively reduce the morbidity and mortality of GC. At present, early screening of GPL can rely on serum tumour markers, such as pepsinogen I/II (PG I/II), glycoantigen 72-4 (CA72-4), glycoantigen 19-9 (CA19-9), glycoantigen 24-2 (CA24-2), glycoantigen 50 (CA50), and gastrin 17 (G-17), and so on, which can reflect gastric mucosal lesions and death rates by detecting the levels of serum tumour markers. The level of serum tumour markers reflects the degree of gastric mucosal lesions and early diagnosis and treatment. Among them, gastrin 17 (G-17) has the highest specificity in GPL screening, and it is found that G-17 can reflect the secretion status and atrophy degree of gastric mucosa in different parts of the stomach, and its serum level decreases with the aggravation of atrophy degree. Therefore, this paper uses “Gastrin, Stomach Neoplasms, Precancerous Conditions, Clinical Studies” as the English Keywords, and “Gastrin, Gastric Cancer, Gastric Precancerous Conditions, Clinical Studies” as the Chinese Keywords to search PubMed and China Knowledge Network (CKN) for the relevant literature in the past 5 years. We discuss the value of G-17 in screening for GPL and provide more references for clinical screening of GPL.

  Key words: Gastrin; Gastric precancerous lesions; Clinical studies; Review

  提交时间：2025-02-18

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 郝雅琴, 胡云峰, 郝静, 赵鑫. 环状RNA与自噬在胃癌中作用的研究进展. 2023. doi: 10.12201/bmr.202304.00001

  王耀强, 汪浩浩, 罗长江. HMGB1在胃癌进展和治疗中的作用. 2024. doi: 10.12201/bmr.202412.00009

  杨高升, 韩晓鹏, 于建平, 王进宝, 王虹宇, 李彦杰. 外泌体在放射性肠损伤中的研究进展. 2025. doi: 10.12201/bmr.202501.00026

  陈传爱. 红细胞存储损伤的研究进展. 2025. doi: 10.12201/bmr.202502.00021

  龚悦, 吴欢, 骆玉霜. 循环肿瘤细胞HER-2表达在胃腺癌靶向治疗中的应用. 2024. doi: 10.12201/bmr.202408.00001

  施呈昊, 屠馨怡, 史佳伟, 陈红爽, 王琴潞, 邹海欧. 大语言模型在临床实践中应用的范围综述. 2024. doi: 10.12201/bmr.202406.00001

  朱健义. 分泌性中耳炎的病因及临床治疗研究进展. 2024. doi: 10.12201/bmr.202407.00018

  郭青霞, 张蕾. 右美托咪定经鼻给药在临床中的研究进展. 2024. doi: 10.12201/bmr.202409.00057

  郑歆. PD-1免疫诱导治疗在不可切除Ⅲ期NSCLC中的研究进展. 2025. doi: 10.12201/bmr.202501.00025

  朱千君, 赵成玉. 尿酸与糖尿病周围神经病变的相关研究进展. 2024. doi: 10.12201/bmr.202408.00019

• 序号	提交日期	编号	操作
  1	2024-10-23	bmr.202502.00030V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论